Bionano preliminary Q1 revenue $7.3-7.5M, up 28-32% YoY; withdraws CPT code applications

Bionano Genomics, Inc.

2023-Q1 EPS reported -$0.12 revenue$7,415,000

Preliminary Q1 revenue $7.3-7.5M, representing 10th consecutive YoY growth quarter.
Saphyr installed base 259 as of March 31 (+47% YoY); 19 systems added in Q1.
Preliminary flowcell sales of 5,226, up 62% over Q1 2022.
Withdraws Category I CPT code applications for OGM to avoid Category III assignment; evaluating new strategy.
Reaffirms FY 2023 guidance: revenue $35-38M and 325 OGM system installed base target.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Bionano Genomics, Inc. reported first quarter ended March 31, 2023 results: revenue between $7.3 and $7.5 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: between $7.3 and $7.5 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-019943

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.